Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ES-1602
- Development stage
- Preclinical
- Lead developer
- Eusol Biotech
- Modality
- Small Molecules
- Administration
- Parenteral
01
Overview
ES-1602 is a preclinical-stage small molecule drug candidate being developed by Eusol Biotech for the treatment of sarcopenia (age-related muscle loss). It is part of the company's Innovation pipeline, which targets unmet needs in aging and CNS disorders. While Eusol Biotech is widely recognized for its In-Situ Forming Depot (ISFD) long-acting injection technology, ES-1602 is categorized as a new drug innovation. As of 2024, specific details regarding its biological target and mechanism of action have not been publicly disclosed, though the company's research portfolio includes the investigation of various pathways for muscle preservation and the treatment of muscle-wasting conditions.
Beyond the preview
Go deeper on ES-1602.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ES-1602.